44.04 USD
-0.11 (-0.25%)
44.1333 USD
+0.09 (+0.21%)
We assign a fundamental rating of 8 out of 10 to EXEL. EXEL was compared to 528 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making EXEL a very profitable company, without any liquidiy or solvency issues. EXEL is evaluated to be cheap and growing strongly. This does not happen too often! This makes EXEL very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year EXEL was profitable.
In the past year EXEL had a positive cash flow from operations.
Each year in the past 5 years EXEL has been profitable.
In the past 5 years EXEL always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 24.01%, EXEL belongs to the best of the industry, outperforming 97.55% of the companies in the same industry.
Looking at the Return On Equity, with a value of 31.37%, EXEL belongs to the top of the industry, outperforming 97.74% of the companies in the same industry.
With an excellent Return On Invested Capital value of 26.31%, EXEL belongs to the best of the industry, outperforming 98.87% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for EXEL is significantly below the industry average of 18.28%.
The last Return On Invested Capital (26.31%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROIC | 26.31% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
EXEL has a better Profit Margin (29.63%) than 95.66% of its industry peers.
EXEL's Profit Margin has declined in the last couple of years.
The Operating Margin of EXEL (35.85%) is better than 97.55% of its industry peers.
EXEL's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 96.63%, EXEL belongs to the top of the industry, outperforming 96.60% of the companies in the same industry.
EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
EXEL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
EXEL has an Altman-Z score of 12.84. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of EXEL (12.84) is better than 84.91% of its industry peers.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.84 |
ROIC/WACC2.98
WACC8.82%
2.3 Liquidity
A Current Ratio of 3.75 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Current ratio (3.75) which is comparable to the rest of the industry.
A Quick Ratio of 3.68 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Quick ratio (3.68) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 |
3. Growth
3.1 Past
EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.93%.
Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 17.51% on average per year.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
3.2 Future
Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 25.68% on average per year.
Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 9.99% on average per year.
EPS Next Y44.91%
EPS Next 2Y30.69%
EPS Next 3Y29.97%
EPS Next 5Y25.68%
Revenue Next Year7.84%
Revenue Next 2Y9.9%
Revenue Next 3Y11.39%
Revenue Next 5Y9.99%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 18.58, which indicates a rather expensive current valuation of EXEL.
94.72% of the companies in the same industry are more expensive than EXEL, based on the Price/Earnings ratio.
EXEL is valuated rather cheaply when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 13.94, EXEL is valued correctly.
Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 96.23% of the companies in the same industry.
EXEL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.92, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.58 | ||
| Fwd PE | 13.94 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaply inside the industry as 96.23% of the companies are valued more expensively.
96.79% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.14 | ||
| EV/EBITDA | 12.01 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
EXEL's earnings are expected to grow with 29.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.41
PEG (5Y)1.47
EPS Next 2Y30.69%
EPS Next 3Y29.97%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
44.04
-0.11 (-0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.46%
Inst Owner Change-0.19%
Ins Owners2.18%
Ins Owner Change-2.56%
Market Cap11.81B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts76.3
Price Target46.18 (4.86%)
Short Float %8.71%
Short Ratio7.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)0.62%
PT rev (3m)2.17%
EPS NQ rev (1m)1.73%
EPS NQ rev (3m)23.46%
EPS NY rev (1m)3.67%
EPS NY rev (3m)10.88%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)0.41%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.58 | ||
| Fwd PE | 13.94 | ||
| P/S | 5.16 | ||
| P/FCF | 15.14 | ||
| P/OCF | 14.93 | ||
| P/B | 5.46 | ||
| P/tB | 5.63 | ||
| EV/EBITDA | 12.01 |
EPS(TTM)2.37
EY5.38%
EPS(NY)3.16
Fwd EY7.17%
FCF(TTM)2.91
FCFY6.6%
OCF(TTM)2.95
OCFY6.7%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.41
PEG (5Y)1.47
Graham Number20.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROCE | 33.48% | ||
| ROIC | 26.31% | ||
| ROICexc | 44.11% | ||
| ROICexgc | 46.12% | ||
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% | ||
| FCFM | 34.08% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 37.81% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 93.06% | ||
| Profit Quality | 115.03% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 | ||
| Altman-Z | 12.84 |
F-Score8
WACC8.82%
ROIC/WACC2.98
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y44.91%
EPS Next 2Y30.69%
EPS Next 3Y29.97%
EPS Next 5Y25.68%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.84%
Revenue Next 2Y9.9%
Revenue Next 3Y11.39%
Revenue Next 5Y9.99%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year54.05%
EBIT Next 3Y25.06%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
Can you provide the valuation status for EXELIXIS INC?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
Can you provide the profitability details for EXELIXIS INC?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
Can you provide the financial health for EXEL stock?
The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.
What is the expected EPS growth for EXELIXIS INC (EXEL) stock?
The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 44.91% in the next year.